Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 2 | 2022 | 972 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 750 | 0.500 |
Why?
|
| Veterans | 4 | 2025 | 1763 | 0.470 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2025 | 101 | 0.440 |
Why?
|
| Diverticulum, Colon | 1 | 2014 | 3 | 0.420 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 15 | 0.410 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 982 | 0.380 |
Why?
|
| Colonic Polyps | 1 | 2014 | 82 | 0.380 |
Why?
|
| Colonoscopy | 1 | 2014 | 243 | 0.350 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 1373 | 0.340 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 262 | 0.340 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 174 | 0.310 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 196 | 0.300 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2023 | 63 | 0.290 |
Why?
|
| Bronchoscopy | 3 | 2015 | 178 | 0.290 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2011 | 160 | 0.290 |
Why?
|
| Duodenum | 2 | 2020 | 111 | 0.270 |
Why?
|
| Lung | 3 | 2011 | 1535 | 0.250 |
Why?
|
| Adenolymphoma | 1 | 2025 | 4 | 0.230 |
Why?
|
| Parotid Neoplasms | 1 | 2025 | 21 | 0.230 |
Why?
|
| Middle Aged | 16 | 2025 | 28601 | 0.220 |
Why?
|
| Influenza, Human | 1 | 2011 | 712 | 0.220 |
Why?
|
| Plasma Cells | 1 | 2025 | 55 | 0.210 |
Why?
|
| Mediastinal Diseases | 1 | 2003 | 14 | 0.200 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.200 |
Why?
|
| Rhabdomyoma | 1 | 2003 | 15 | 0.190 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 393 | 0.180 |
Why?
|
| Scalp | 1 | 2022 | 59 | 0.180 |
Why?
|
| Mouth Neoplasms | 1 | 2003 | 105 | 0.170 |
Why?
|
| Carcinoma | 1 | 2023 | 291 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 357 | 0.160 |
Why?
|
| Cell Degranulation | 1 | 2020 | 27 | 0.160 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 680 | 0.160 |
Why?
|
| Male | 19 | 2025 | 64957 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1545 | 0.160 |
Why?
|
| Eosinophils | 1 | 2020 | 122 | 0.150 |
Why?
|
| Dyspepsia | 1 | 2020 | 109 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2020 | 112 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 2065 | 0.130 |
Why?
|
| Emphysema | 2 | 2009 | 67 | 0.130 |
Why?
|
| Humans | 24 | 2025 | 131163 | 0.130 |
Why?
|
| Biopsy, Needle | 3 | 2013 | 204 | 0.120 |
Why?
|
| Celiac Disease | 1 | 2016 | 73 | 0.110 |
Why?
|
| Granuloma, Giant Cell | 1 | 2015 | 12 | 0.110 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 155 | 0.110 |
Why?
|
| Salivary Glands, Minor | 1 | 2015 | 8 | 0.110 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 45 | 0.110 |
Why?
|
| Image-Guided Biopsy | 1 | 2015 | 38 | 0.110 |
Why?
|
| Endosonography | 1 | 2015 | 75 | 0.110 |
Why?
|
| Klatskin Tumor | 1 | 2014 | 10 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2014 | 352 | 0.100 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 12 | 0.100 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2014 | 103 | 0.100 |
Why?
|
| Leukocytosis | 1 | 2014 | 46 | 0.100 |
Why?
|
| Gastritis | 1 | 2017 | 374 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 47 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 279 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 126 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 357 | 0.090 |
Why?
|
| Female | 10 | 2025 | 70963 | 0.090 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 130 | 0.090 |
Why?
|
| Smoking | 3 | 2025 | 932 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17753 | 0.090 |
Why?
|
| Esophagoscopy | 1 | 2013 | 180 | 0.090 |
Why?
|
| Gout | 1 | 2015 | 169 | 0.090 |
Why?
|
| Tracheal Neoplasms | 1 | 2012 | 21 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 223 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2012 | 39 | 0.090 |
Why?
|
| Debridement | 1 | 2012 | 95 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1287 | 0.080 |
Why?
|
| Aged | 9 | 2025 | 21025 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 281 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 587 | 0.080 |
Why?
|
| Anemia | 1 | 2014 | 354 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 80 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 71 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 153 | 0.070 |
Why?
|
| Barrett Esophagus | 1 | 2013 | 357 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 388 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2023 | 426 | 0.070 |
Why?
|
| Motor Activity | 1 | 2010 | 489 | 0.070 |
Why?
|
| Elastin | 1 | 2007 | 32 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2009 | 439 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 356 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2007 | 175 | 0.060 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2025 | 9 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2010 | 381 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1591 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2010 | 715 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6797 | 0.050 |
Why?
|
| Macrophages, Alveolar | 1 | 2004 | 52 | 0.050 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2003 | 9 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2004 | 158 | 0.050 |
Why?
|
| Fiber Optic Technology | 1 | 2003 | 43 | 0.050 |
Why?
|
| Receptor, trkC | 1 | 2023 | 13 | 0.050 |
Why?
|
| Gingiva | 1 | 2023 | 10 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 36 | 0.050 |
Why?
|
| Pulmonary Emphysema | 1 | 2004 | 96 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2023 | 58 | 0.050 |
Why?
|
| Lymphangioma | 1 | 2003 | 21 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 744 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 5063 | 0.040 |
Why?
|
| Hemangioma | 1 | 2003 | 86 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 743 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 344 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2007 | 650 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 236 | 0.040 |
Why?
|
| Adult | 5 | 2025 | 31282 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 2701 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2013 | 1211 | 0.040 |
Why?
|
| Logistic Models | 1 | 2003 | 1797 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 3829 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1882 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3748 | 0.030 |
Why?
|
| United States | 3 | 2020 | 12072 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 162 | 0.030 |
Why?
|
| Ethmoid Bone | 1 | 2015 | 8 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 1586 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 5196 | 0.030 |
Why?
|
| Maxilla | 1 | 2015 | 40 | 0.030 |
Why?
|
| Uric Acid | 1 | 2015 | 110 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 156 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 336 | 0.030 |
Why?
|
| Time Factors | 2 | 2014 | 6196 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 43 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 387 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2015 | 317 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 272 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 631 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 423 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 563 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 305 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 2602 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 28 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 463 | 0.020 |
Why?
|
| Equipment Design | 1 | 2012 | 512 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1356 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1490 | 0.020 |
Why?
|
| Risk Factors | 2 | 2017 | 11074 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 124 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 370 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 332 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 224 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1272 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2904 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2304 | 0.020 |
Why?
|
| Mice | 1 | 2025 | 18301 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 1634 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 239 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2825 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 3360 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2007 | 236 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 47 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 38 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 40 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2004 | 52 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 509 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 3711 | 0.010 |
Why?
|
| Animals | 1 | 2025 | 33912 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1489 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 1796 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 4066 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 1339 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 1722 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 2200 | 0.010 |
Why?
|